NTRP vs. HPCO, MCOM, BON, TRNR, SGBX, SBET, CLEU, MICS, GXAI, and NVFY
Should you be buying Neurotrope stock or one of its competitors? The main competitors of Neurotrope include Hempacco (HPCO), Micromobility.com (MCOM), Bon Natural Life (BON), Interactive Strength (TRNR), Safe & Green (SGBX), SharpLink Gaming (SBET), China Liberal Education (CLEU), Singing Machine (MICS), Gaxos.ai (GXAI), and Nova LifeStyle (NVFY). These companies are all part of the "consumer discretionary" sector.
Hempacco (NASDAQ:HPCO) and Neurotrope (NASDAQ:NTRP) are both small-cap consumer discretionary companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
7.6% of Hempacco shares are held by institutional investors. Comparatively, 3.8% of Neurotrope shares are held by institutional investors. 58.8% of Hempacco shares are held by insiders. Comparatively, 9.7% of Neurotrope shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Hempacco has a net margin of -439.42% compared to Hempacco's net margin of -1,123.90%. Neurotrope's return on equity of -113.86% beat Hempacco's return on equity.
Hempacco has higher revenue and earnings than Neurotrope. Neurotrope is trading at a lower price-to-earnings ratio than Hempacco, indicating that it is currently the more affordable of the two stocks.
In the previous week, Neurotrope had 1 more articles in the media than Hempacco. MarketBeat recorded 1 mentions for Neurotrope and 0 mentions for Hempacco. Neurotrope's average media sentiment score of 0.00 equaled Hempacco'saverage media sentiment score.
Neurotrope received 180 more outperform votes than Hempacco when rated by MarketBeat users.
Hempacco has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Neurotrope has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.
Summary
Hempacco beats Neurotrope on 9 of the 13 factors compared between the two stocks.
Get Neurotrope News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurotrope Competitors List
Related Companies and Tools
